Stock options cloud the picture because they don't show up properly on the income statement and the stockholders in general don't realize the dilution they cause.
Just to be clear: The Copaxone incentives we were discussing in this thread consist of shares, not options. The fair-market value of the shares is a GAAP expense item on the income statement.